8-K: Arcus Biosciences Reports Promising Data and Solid Financial Position in Q4 and Full Year 2024 Results

Arcus Biosciences announces positive clinical data for casdatifan, initiation of a Phase 3 study, and a strong cash position of $992 million as of December 31, 2024.

Summary

• Arcus Biosciences reported its fourth-quarter and full-year 2024 financial results and provided a pipeline update.
• New data from the Phase 1/1b ARC-20 study showed that casdatifan improved upon the rate of primary progression, overall response rate (ORR), and progression-free survival (PFS) relative to published data from studies with HIF-2a inhibitors to date.
• The company expects to initiate a Phase 3 study (PEAK-1) for casdatifan in combination with cabozantinib versus cabozantinib in immuno-oncology (IO)-experienced patients with clear cell renal cell carcinoma (ccRCC) in the first half of 2025.
• Initial data from the cohort of ARC-20 evaluating casdatifan plus cabozantinib are expected to be presented in mid-2025.
• Arcus completed a $150 million financing and had $992 million in cash, cash equivalents, and marketable securities as of December 31, 2024, excluding proceeds from the offering.
• Revenues for the fourth quarter of 2024 were $36 million, compared to $31 million for the same period in 2023.
• Research and Development (R&D) expenses were $111 million for the fourth quarter of 2024, compared to $93 million for the same period in 2023.
• Net loss for the fourth quarter of 2024 was $94 million, compared to $81 million for the same period in 2023.
• Arcus expects its cash and investments, together with the proceeds from the equity financing in February 2025, will provide funding through initial pivotal read-outs for domvanalimab, quemliclustat and casdatifan including STAR-221, PRISM-1 and PEAK-1.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook due to promising clinical data, a strong cash position, and advancement of multiple programs into Phase 3 trials. However, increased R&D expenses and net losses temper the overall sentiment.

Positives

• Strong cash position of $992 million provides financial flexibility to advance pipeline programs.
• Positive clinical data for casdatifan supports its potential as a best-in-class HIF-2a inhibitor.
• Advancement of multiple programs into Phase 3 trials (PEAK-1, PRISM-1) indicates progress in clinical development.
• Collaboration with Gilead continues to provide financial and strategic support.
• Revenue increased to $36 million for the fourth quarter of 2024, compared to $31 million for the same period in 2023.

Negatives

• Net loss increased to $94 million for the fourth quarter of 2024, compared to $81 million for the same period in 2023.
• R&D expenses increased to $111 million for the fourth quarter of 2024, compared to $93 million for the same period in 2023.

Risks

• The success of Arcus's pipeline depends on positive results from ongoing and planned clinical trials.
• The company is dependent on collaborations with third parties, such as Gilead and Taiho, for the development and commercialization of its products.
• Changes in the competitive landscape could impact the success of Arcus's programs.
• The inherent uncertainty associated with pharmaceutical product development and clinical trials could lead to delays or failures.

Future Outlook

Arcus expects its cash and investments, together with the proceeds from the equity financing in February 2025, will provide funding through initial pivotal read-outs for domvanalimab, quemliclustat and casdatifan including STAR-221, PRISM-1 and PEAK-1. The company anticipates several data readouts and study initiations in the coming years.

Management Comments

• Terry Rosen, Ph.D., chief executive officer of Arcus, stated that casdatifan has the potential to be a best-in-class profile.
• Dr. Rosen believes casdatifan can play an important role in the treatment of every patient diagnosed with ccRCC given the strong efficacy and preferable safety profile relative to standard-of-care VEGFR tyrosine kinase inhibitors.
• Arcus is pursuing a robust development plan in multiple ccRCC settings, including the Phase 3 trial, PEAK-1, and a clinical collaboration with AstraZeneca.
• Arcus continues to evaluate and pursue opportunities to conserve capital and allocate greater resources to maximizing the potential of casdatifan.

Industry Context

Arcus Biosciences is focused on developing differentiated molecules and combination therapies for cancer, aligning with the industry trend of exploring novel immuno-oncology approaches and combination strategies to improve patient outcomes. The company's focus on TIGIT, PD-1, HIF-2a, CD73, A2a/A2b receptors, CD39 and AXL targets reflects the growing interest in these pathways as potential therapeutic targets.

Comparison to Industry Standards

• The reported ORR and PFS data for casdatifan monotherapy in ccRCC patients who have progressed on both an anti-PD-1 and a TKI therapy are being compared to published data from studies with other HIF-2a inhibitors, suggesting a potential for best-in-class performance.
• The initiation of the Phase 3 PEAK-1 study evaluating casdatifan in combination with cabozantinib versus cabozantinib alone in IO-experienced ccRCC patients is a standard approach in the field, similar to trials conducted by companies like Exelixis (cabozantinib developer) and Bristol Myers Squibb (nivolumab developer).
• Arcus's collaboration with AstraZeneca to evaluate casdatifan in combination with volrustomig, AstraZenecas investigational PD-1/CTLA-4 bispecific antibody, is in line with the industry trend of exploring bispecific antibodies in combination with other therapies to enhance efficacy.

Stakeholder Impact

• Shareholders: The positive clinical data and strong financial position are likely to be viewed favorably by shareholders.
• Employees: Advancement of pipeline programs and financial stability could boost employee morale.
• Patients: Successful development of new therapies could provide new treatment options for cancer patients.
• Collaborators: Continued collaboration with Gilead and Taiho is essential for the development and commercialization of Arcus's products.

Next Steps

• Initiate Phase 3 PEAK-1 study in the first half of 2025.
• Initiate three new expansion cohorts within ARC-20 in the first quarter of 2025.
• Meet with the FDA to clarify next steps for ARC-9 in the first half of 2025.
• Present initial data from the ARC-20 cohort evaluating casdatifan plus cabozantinib in mid-2025.
• Advance AB801 into expansion cohorts in NSCLC in the second half of 2025.
• Present overall survival data from the Phase 2 EDGE-Gastric study in the fall of 2025.
• Present the first Phase 3 data readout for domvanalimab plus zimberelimab from the STAR-221 study in 2026.

Key Dates